Illumina CEO Says Next Round of GWAS Will Be Done on Arrays, Not Sequencers
January 19, 2010
Illumina CEO Says Next Round of GWAS Will Be Done on Arrays, Not Sequencers
While there is enthusiasm for the firm's sequencing instruments, Illumina believes arrays are currently "faster," "cheaper," and "more accurate" than existing next-generation sequencers for genome-wide association studies.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Q&A: Oxford's Mark McCarthy on Using Exome Arrays and Exome Sequencing to Study Diabetes
May 28, 2013 / BioArray News - Q&A: Chinese GWAS Expert Yongyong Shi Makes the Case for Population-Specific Arrays
December 18, 2012 / BioArray News - Illumina Predicts Flat Future for Array Business as GWAS Decline Counters Growth in New Markets
October 30, 2012 / BioArray News - Illumina CEO Discusses ENCODE, GWAS, and NIH Funding at Investor Conference
September 18, 2012 / BioArray News - Illumina's Array Business Flat in Q2 as Demand for Exome, Ag Chips Offsets Decline in GWAS
July 31, 2012 / BioArray News